atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10 per share to raise proceeds of $55 million.
The underwriter has a 30-day option to purchase up to an additional approximately 3.9 million shares.
The company intends to use the proceeds from the offering for general corporate purposes, including working capital and to advance its clinical programs.
The offering is set to close on February 14. Berenberg is acting as the sole bookrunner for the offering.